Research Article

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease†

  1. Yaroslau Compta MD1,
  2. María J. Martí MD, PhD1,*,
  3. Naroa Ibarretxe-Bilbao PhD2,
  4. Carme Junqué PhD2,
  5. Francesc Valldeoriola MD, PhD1,
  6. Esteban Muñoz MD, PhD1,
  7. Mario Ezquerra PhD1,
  8. Jose Ríos BSc3,
  9. Eduardo Tolosa MD, FRCP1

Article first published online: 30 SEP 2009

DOI: 10.1002/mds.22594

Issue

Movement Disorders

Movement Disorders

Volume 24, Issue 15, pages 2203–2210, 15 November 2009

Additional Information

How to Cite

Compta, Y., Martí, M. J., Ibarretxe-Bilbao, N., Junqué, C., Valldeoriola, F., Muñoz, E., Ezquerra, M., Ríos, J. and Tolosa, E. (2009), Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord., 24: 2203–2210. doi: 10.1002/mds.22594

Author Information

  1. 1

    Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, Barcelona, Catalonia, Spain

  2. 2

    Department of Psychiatry and Clinical Psychobiology IDIBAPS, CIBERNED, Faculty of Medicine, University of Barcelona, Catalonia, Spain

  3. 3

    Statistics and Methodologic Support Unit, Unitat d'Avaluació, Suport i Prevenció (UASP), Hospital Clínic, IDIBAPS, Barcelona, Catalonia, Spain

*Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, c./Villarroel 170, 08036 Barcelona, Spain

  1. †

    Potential conflict of interest: None reported.

Publication History

  1. Issue published online: 19 NOV 2009
  2. Article first published online: 30 SEP 2009
  3. Manuscript Accepted: 17 MAR 2009
  4. Manuscript Revised: 11 MAR 2009
  5. Manuscript Received: 12 JAN 2009

Funded by

  • Fundacio la Marato de TV3 2006. Grant Number: N-2006-TV060510
  • Spanish Neurology Society (SEN)
  • Naroa Ibarretxe-Bilbao
  • Spanish Ministry of Education and Science. Grant Number: AP2005-0191
  • Laboratory of Experimental Neurology

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (126K)

Keywords:

  • Parkinson's disease;
  • dementia;
  • cerebrospinal fluid;
  • tau;
  • beta-amyloid;
  • neuropsychological function

Abstract

Alzheimer's disease (AD)-pathology may play a role in Parkinson's disease (PD)-related dementia (PDD). The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau, phospho-tau, and beta-amyloid, proposed AD biomarkers, and their relationship with cognitive function in PD. Forty PD patients [20 nondemented (PDND); 20 PDD] and 30 controls underwent CSF tau, phospho-tau, and beta-amyloid analysis using specific ELISA techniques. All PD patients and 15 controls underwent neuropsychological testing of fronto-subcortical (attention, fluency) and neocortical (memory, naming, visuoperceptive) functions. CSF markers levels were compared between groups, and compared and correlated with neuropsychological measures in PDND and PDD separately and as a continuum (PD). CSF tau and phospho-tau were higher in PDD than in PDND and controls (P < 0.05). CSF beta-amyloid ranged from high (controls) to intermediate (PDND) and low (PDD) levels (P < 0.001). In all PD and PDD patients, high CSF tau and phospho-tau were associated with impaired memory and naming. In PDND, CSF beta-amyloid was related with phonetic fluency. These findings suggest underlying AD-pathology in PDD in association with cortical cognitive dysfunction, and that low CSF beta-amyloid in PDND patients with impaired phonetic fluency can constitute an early marker of cognitive dysfunction. © 2009 Movement Disorder Society

View Full Article with Supporting Information (HTML) Get PDF (126K)